Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 210,202 shares of the company's stock after selling 14,743 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.73% of Krystal Biotech worth $32,930,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Covestor Ltd increased its position in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares during the last quarter. KBC Group NV grew its stake in Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. grew its stake in Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after purchasing an additional 433 shares in the last quarter. US Bancorp DE grew its stake in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares in the last quarter. Finally, Certuity LLC acquired a new position in Krystal Biotech in the fourth quarter worth about $214,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 1.2%

KRYS stock traded up $1.45 during midday trading on Friday, reaching $127.06. The company had a trading volume of 380,465 shares, compared to its average volume of 309,934. The stock has a 50 day moving average price of $154.86 and a 200 day moving average price of $164.67. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The firm has a market capitalization of $3.67 billion, a PE ratio of 42.49 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Chardan Capital reiterated a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 6th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $211.13.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).